Alterations in Zn²⁺ concentration are seen in normal tissues and in disease states, and for this reason imaging of Zn²⁺ is an area of active investigation. Herein, enriched [1-¹³ C]cysteine and [1-¹³ C₂ ]iminodiacetic acid were developed as Zn²⁺ -specific imaging probes using hyperpolarized ¹³ C magnetic resonance spectroscopy. [1-¹³ C]cysteine was used to accurately quantify Zn²⁺ in complex biological mixtures. These sensors can be employed to detect Zn²⁺ via imaging mechanisms including changes in ¹³ C chemical shift, resonance linewidth, or T₁ .

Boron neutron capture therapy (BNCT) is a therapeutic modality which has been used for the treatment of cancers, including brain and head and neck tumors. For effective treatment via BNCT, efficient and selective delivery of a high boron dose to cancer cells is needed. Prostate-specific membrane antigen (PSMA) is a target for prostate cancer imaging and drug delivery. In this study, we conjugated boronic acid or carborane functional groups to a well-established PSMA inhibitor scaffold to deliver boron to prostate cancer cells and prostate tumor xenograft models. Eight boron-containing PSMA inhibitors were synthesized. All of these compounds showed a strong binding affinity to PSMA in a competition radioligand binding assay (IC₅₀ from 555.7 to 20.3 nM). Three selected compounds 1a, 1d, and 1f were administered to mice, and their in vivo blocking of ⁶⁸Ga-PSMA-11 uptake was demonstrated through a positron emission tomography (PET) imaging and biodistribution experiment. Biodistribution analysis demonstrated boron uptake of 4-7 μg/g in 22Rv1 prostate xenograft tumors and similar tumor/muscle ratios compared to the ratio for the most commonly used BNCT compound, 4-borono-l-phenylalanine (BPA). Taken together, these data suggest a potential role for PSMA targeted BNCT agents in prostate cancer therapy following suitable optimization.